Seeking Alpha
07 Jul 2026, 12:40 UTC · 11w ago
Verdict
Headline takes no side. We score RNA +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 74% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Pivotal data for Avidity's del-brax and Ionis's pelacarsen is expected in the second half of the year.
More positive than 93% of claims this week
Novartis acquired Myricx Bio to expand its ADC pipeline with novel NMTi payloads.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 51% of claims this week
Novartis is maintaining a strategic preference for in-licensing and bolt-on acquisitions.
More positive than 42% of claims this week
Which stocks this story touches
More positive than 74% of ticker scores this week
Possesses a late-stage asset with multibillion-dollar peak sales potential and upcoming pivotal data.
More positive than 74% of ticker scores this week
Possesses a late-stage asset with multibillion-dollar peak sales potential and upcoming pivotal data.
More positive than 58% of ticker scores this week
Expansion of ADC pipeline through the acquisition of Myricx Bio is a positive strategic move.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
4h ago
−36.0%
Price is moving against the score
$8.33 vs $13.01 close before publication (Jul 6) · not market-adjusted
RNA chart →
